首页> 美国卫生研究院文献>Temperature: Multidisciplinary Biomedical Journal >Platelet-activating factor is a potent pyrogen and cryogen but it does not mediate lipopolysaccharide fever or hypothermia
【2h】

Platelet-activating factor is a potent pyrogen and cryogen but it does not mediate lipopolysaccharide fever or hypothermia

机译:血小板激活因子是有效的热原和致冷剂但它不介导脂多糖热或体温过低

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We examined whether platelet-activating factor (PAF) and its receptor mediate lipopolysaccharide (LPS)-induced fever and hypothermia in rats. Two highly potent, structurally distinct antagonists of the PAF receptor, CV6209 and WEB2086, were used. At a neutral ambient temperature (Ta) of 30ºC, administration of LPS at a low (10 μg/kg, i.v.) or high (1,000 μg/kg, i.v.) dose resulted in fever. The response to the high dose was turned into hypothermia at a subneutral Ta of 22ºC. Neither LPS-induced fever nor hypothermia was affected by pretreatment with CV6209 (5 mg/kg, i.v.) or WEB2086 (5 mg/kg, i.v.). However, both PAF antagonists were efficacious in blocking the thermoregulatory response caused by PAF (334 pmol/kg/min, 1 h, i.v.), regardless of whether the response was a fever (at 30ºC) or hypothermia (at 22ºC). Additional experiments showed that the thermoregulatory responses to LPS and PAF are also distinct in terms of their mediation by prostaglandins. Neither PAF fever nor PAF hypothermia was affected by pretreatment with the cyclooxygenase-2 inhibitor SC236 (5 mg/kg, i.p.), which is known to abrogate LPS fever. The responses to PAF were also unaffected by pretreatment with the cyclooxygenase-1 inhibitor SC560 (5 mg/kg, i.p.), which is known to attenuate LPS hypothermia. In conclusion, PAF infusion at a picomolar dose causes fever at thermoneutrality but hypothermia in a subthermoneutral environment, both responses being dependent on the PAF receptor and independent of prostaglandins. However, the PAF receptor does not mediate LPS-induced fever or hypothermia, thus challenging the dogma that PAF is an upstream mediator of responses to LPS.
机译:我们检查了血小板活化因子(PAF)及其受体是否介导了大鼠脂多糖(LPS)引起的发烧和体温过低。使用了PAF受体的两种高效,结构独特的拮抗剂CV6209和WEB2086。在30°C的中性环境温度(Ta)下,以低剂量(10μg/ kg,i.v.)或高剂量(1,000μg/ kg,i.v.)施用LPS会导致发烧。在Ta中性温度为22ºC时,对高剂量的反应转变为低温。使用CV6209(5 mg / kg,静脉内)或WEB2086(5 mg / kg,静脉内)预处理均不会影响LPS引起的发烧或体温过低。但是,两种PAF拮抗剂都能有效阻止PAF引起的体温调节反应(334 pmol / kg / min,1小时,i.v.),无论响应是发烧(30ºC)还是体温过低(22ºC)。另外的实验表明,对LPS和PAF的温度调节反应在前列腺素介导方面也很明显。 PAF发热和PAF体温过低均不受环加氧酶2抑制剂SC236(5 mg / kg,i.p.)预处理的影响,已知该抑制剂可消除LPS发热。对PAF的反应也不受环加氧酶-1抑制剂SC560(5 mg / kg,i.p.)预处理的影响,已知该抑制剂可减弱LPS的体温过低。总之,以皮摩尔剂量输注PAF会导致热中性发热,而在亚中温环境下会出现体温过低,这两种反应均依赖于PAF受体且不依赖于前列腺素。但是,PAF受体不会介导LPS引起的发烧或体温过低,因此挑战了一条教条,即PAF是对LPS应答的上游介质。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号